Curcumin compound reactivates Epstein–Barr virus, offering safer cancer therapy

A novel curcumin derivative, C210, activates the Epstein–Barr virus (EBV) lytic cycle without producing infectious virions by disrupting HSP90. This discovery opens avenues for safer EBV-positive cancer therapies.

Not all ultra-processed foods are made alike: Researchers warn against villainizing entire food group

Researchers find that ultra-processed food (UPF) consumption may not be directly responsible for poor health outcomes, with lifestyle factors playing a significant role. More experimental

September 30, 2024

AI tools and a desire to do more with less is expected to drive health systems’ 2024 tech spend

Hospitals and clinics are expecting a slightly better 2024 compared to last year thanks to a return to mostly in-person care, patients resuming preventive visits

January 3, 2024

Taysha teases early gene therapy data for Rett syndrome

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.